# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $52 to $30.
B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from...
Goldman Sachs analyst Matthew Sykes maintains 10x Genomics (NASDAQ:TXG) with a Sell and lowers the price target from $30 to ...
TD Cowen analyst Dan Brennan downgrades 10x Genomics (NASDAQ:TXG) from Buy to Hold and lowers the price target from $57 to $32.
Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $63 to $53.
The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 269739...
10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.48)...